13F Holdings
中文EN

ALVO Alvotech IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1898416 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY19.7%
TTM net income YoY112.0%
TTM EPS YoY111.5%
Revenue 3-yr CAGR91.9%
Net income 3-yr CAGR—

Margins

Gross margin59.8%
Operating margin13.3%
Net margin4.8%
FCF margin-19.6%
EBITDA margin19.8%

Returns

ROE—
ROA2.1%
ROIC (approx.)5.4%
Asset turnover0.43x

Leverage & solvency

Liabilities / assets119.1%
Debt / equity—
Current ratio1.89x
Interest coverage0.52x

Cash quality & payout

Operating cash flow / net income-1.80x
Accruals ratio5.8%
Payout ratio0.0%
Capex / revenue11.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$586.32M$489.68M$91.43M$83.03M$36.77M
Cost of revenue$235.56M$185.31M$160.86M$64.09M$0
Gross profit$350.76M$304.37M-$69.42M$18.93M$36.77M
R&D expense$184.19M$171.31M$210.83M$180.62M$191.01M
SG&A expense$90.95M$65.71M$76.56M$186.74M$84.13M
Operating income$78.21M$69.64M-$354.86M-$346.44M-$235.46M
Interest expense$149.19M$303.17M$267.16M$188.42M$117.36M
Pretax income$136.35M-$217.56M-$651.05M-$551.65M-$149.20M
Income tax$108.43M$14.30M-$99.32M-$38.07M-$47.69M
Net income$27.92M-$231.86M-$551.73M-$513.58M-$101.50M
EBITDA$116.06M$100.94M-$330.65M-$326.03M-$217.26M
EPS (basic)0.10-0.87-2.43-2.60-0.92
EPS (diluted)0.10-0.87-2.43-2.60-0.92
Weighted avg. shares (diluted)291.34M267.92M227.26M197.72M110.67M
Balance sheet
Cash & equivalents$172.36M$51.43M$11.16M$66.43M$17.56M
Receivables$69.74M$160.22M$41.29M$32.97M$29.40M
Inventory$220.05M$127.89M$74.43M$71.47M$39.06M
Current assets$574.01M$455.02M$194.84M$230.74M$119.82M
PP&E, netmay include right-of-use assets (IFRS)$356.40M$284.55M$236.78M$220.59M$78.53M
Goodwill$12.84M$11.33M$12.06M$11.64M$12.37M
Intangibles$81.83M$20.62M$19.08M$25.65M$21.51M
Total assets$1.49B$1.22B$950.09M$828.44M$597.98M
Current liabilities$304.08M$193.40M$260.95M$167.29M$111.84M
Short-term debt$36.92M$32.70M$38.02M$19.92M$2.77M
Long-term debt$1.26B$1.04B$922.13M$744.65M$398.14M
Total debt$1.30B$1.07B$960.16M$764.57M$400.91M
Total liabilities$1.77B$1.63B$1.88B$1.39B$733.59M
Shareholders' equity-$284.49M-$412.77M-$932.49M-$564.42M-$135.61M
Net debt$1.13B$1.02B$949.00M$698.14M$383.36M
Shares outstanding312.02M301.81M266.82M252.16M893,060
Cash flow statement
Operating cash flow-$50.20M-$236.84M-$312.19M-$312.39M-$228.17M
Capital expenditure$64.47M$53.66M$33.23M$37.88M$20.46M
Free cash flow-$114.67M-$290.50M-$345.42M-$350.27M-$248.63M
Investing cash flow-$104.22M-$18.87M-$46.34M-$63.54M-$40.63M
Financing cash flow$270.83M$297.31M$301.32M$424.91M$254.83M
Depreciation & amortization$37.85M$31.30M$24.21M$20.41M$18.20M
Stock-based compensation$7.38M$7.63M$18.03M$10.32M$0
Dividends paid$0$0$0$0$0

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.